No profile data available.
Genelux Corporation (GNLX) is a healthcare company in the additional cancer treatment drugs industry, based in Westlake Village, United States, with about 25 full-time employees.
It reported revenue of $8,000 for fiscal year 2025, about flat from fiscal year 2024, and net income of -$32.15 million. Its market capitalization was $115.83 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Genelux reported $8,000 in revenue for fiscal year 2025, about flat from $8,000 in fiscal year 2024.
$115.83 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Inovio Pharmaceuticals, Inc. (INO), Foghorn Therapeutics Inc. (FHTX), enGene Holdings Inc. (ENGN), PMV Pharmaceuticals, Inc. (PMVP).